Anthropic's Claude Discovers Novel CRISPR-Like Enzyme System in Phage DNA

Anthropic said its Claude model has flagged a previously uncharacterized enzyme system buried in bacteriophage DNA, the first result out of the company's new in-house biology lab. The finding puts AI-driven drug discovery back in the spotlight, and puts a familiar list of gene-editing names back on watch.

What Claude actually found

Anthropic says the pattern marks a previously uncharacterized enzyme system found in bacteriophages, the viruses that infect bacteria, which the team is calling array-associated reverse transcriptases, or ART.

The ART system consists of three parts: the reverse transcriptase, a partner gene beside it, and a long array of evenly spaced DNA repeat sequences. That repeat layout resembles a CRISPR array, which holds the RNA bank that makes CRISPR-Cas systems programmable.

The company does not yet know what the system does. Anthropic announced the result in a blog post and a preprint that has not been peer reviewed.

How the AI did it

To find ART, Claude agents screened more than 200,000 reverse transcriptases, selected 3,500 candidate systems, then narrowed those to 20 for detailed reports. Anthropic says roughly 950 agents searched for 21 hours, using 210 million tokens.

The agents proceeded much as a human scientist would, counting the repeats, measuring their spacing, comparing the layout with known RT systems, and searching the literature for any previous report of the pattern before filing a report for human review.

Do you want to see how to make more plays? Do you want to find gains yourself?

Unusual Whales helps you find market opportunities through our market tide, historical options flow, GEX, and much, much more.

Create a free account here to start conquering the market with Unusual Whales.

Why traders should care

Anthropic introduced a new life sciences research group and laboratory on September 23, 2026, formed in the spring of 2026 to test whether general AI models can systematize and accelerate biological discovery. The company said it believes acceleration will come from AI agents collaborating with humans at every step, which required building its own lab.

Translation for markets: this is Anthropic staking a claim in AI-for-biology, the same lane where Alphabet's Isomorphic Labs and a growing list of biotech platforms are competing. Any credible AI-discovered biology result tends to move sentiment across gene-editing and AI infrastructure names.

The CRISPR context

The arrangement resembles features seen in CRISPR, raising the possibility that scientists may have found another natural mechanism capable of manipulating genetic material. But researchers do not yet know exactly what the newly identified system does. The discovery is not a new gene-editing treatment or a replacement for CRISPR, but an early-stage finding that scientists now need to investigate experimentally.

First experiments found that the ART array produces distinct short RNAs, adding a lab observation to the sequence-based finding, though it does not settle what those RNAs do or what the enzyme system is for. Anthropic says experiments to determine ART's primary function are continuing.

Options market and stocks to watch

A few names sit at the intersection of AI compute and gene-editing that traders may want on the radar:

• CRSP — CRISPR Therapeutics is the pure-play name most directly tied to any headline about new CRISPR-like systems. Watch for sentiment-driven moves on flow.
• NTLA — Intellia Therapeutics, another gene-editing bellwether that tends to trade in sympathy with CRSP on platform news.
• BEAM — Beam Therapeutics, base-editing focused, watch for correlated moves if the ART narrative gains traction.
• GOOGL — Alphabet's Isomorphic Labs is the most direct public-market comp to Anthropic's biology push. Watch for competitive framing.
• NVDA — Every large-agent AI biology workload runs on GPUs. Continued proof points for agent swarms reinforce the compute demand thesis.

For more, see other coverage on Unusual Whales news.

Want more market intelligence? Create your free Unusual Whales account for options flow, market tide, GEX, and the full toolkit.